Literature DB >> 12037137

International Union of Pharmacology. XXIX. Update on endothelin receptor nomenclature.

Anthony P Davenport1.   

Abstract

In mammals, the endothelin (ET) family comprises three endogenous isoforms, ET-1, ET-2, and ET-3. ET-1 is the principal isoform in the human cardiovascular system and remains the most potent and long-lasting constrictor of human vessels discovered. In humans, endothelins mediate their actions via only two receptor types that have been cloned and classified as the ET(A) and ET(B) receptors in the first NC-IUPHAR (International Union of Pharmacology Committee on Receptor Nomenclature and Drug Classification) report on nomenclature in 1994. This report was compiled before the discovery of the majority of endothelin receptor antagonists (particularly nonpeptides) currently used in the characterization of receptors and now updated in the present review. Endothelin receptors continue to be classified according to their rank order of potency for the three endogenous isoforms of endothelin. A selective ET(A) receptor agonist has not been discovered, but highly selective antagonists include peptides (BQ123, cyclo-[D-Asp-L-Pro-D-Val-L-Leu-D-Trp-]; FR139317, N- [(hexahydro-1-azepinyl)carbonyl]L-Leu(1-Me)D-Trp-3 (2-pyridyl)-D-Ala) and the generally more potent nonpeptides, such as PD156707, SB234551, L754142, A127722, and TBC11251. Sarafotoxin S6c, BQ3020 ([Ala(11,15)]Ac-ET-1((6-21))), and IRL1620 [Suc-(Glu(9), Ala(11,15))-ET-1((8-21))] are widely used synthetic ET(B) receptor agonists. A limited number of peptide (BQ788) and nonpeptide (A192621) ET(B) antagonists have also been developed. They are generally less potent than ET(A) antagonists and display lower selectivity (usually only 1 to 2 orders of magnitude) for the ET(B) receptor. Radioligands highly selective for either ET(A) ((125)I-PD151242, (125)I-PD164333, and (3)H-BQ123) or ET(B) receptors ((125)I-BQ3020 and (125)I-IRL1620) have further consolidated classification into only these two types, with no strong molecular or pharmacological evidence to support the existence of further receptors in mammals.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12037137     DOI: 10.1124/pr.54.2.219

Source DB:  PubMed          Journal:  Pharmacol Rev        ISSN: 0031-6997            Impact factor:   25.468


  61 in total

1.  ET-1 induced Elevation of intracellular calcium in clonal neuronal and embryonic kidney cells involves endogenous endothelin-A receptors linked to phospholipase C through Gα(q/11).

Authors:  Jean-Pierre Montmayeur; Travis P Barr; Sarah A Kam; Samuel J Packer; Gary R Strichartz
Journal:  Pharmacol Res       Date:  2011-04-14       Impact factor: 7.658

Review 2.  Ion channels and signaling in the pituitary gland.

Authors:  Stanko S Stojilkovic; Joël Tabak; Richard Bertram
Journal:  Endocr Rev       Date:  2010-07-21       Impact factor: 19.871

3.  Lactoferrin-endothelin-1 axis contributes to the development and invasiveness of triple-negative breast cancer phenotypes.

Authors:  Ngoc-Han Ha; Vasudha S Nair; Divijendra Natha Sirigiri Reddy; Prakriti Mudvari; Kazufumi Ohshiro; Krishna Sumanth Ghanta; Suresh B Pakala; Da-Qiang Li; Luis Costa; Allan Lipton; Rajendra A Badwe; Suzanne Fuqua; Margaretha Wallon; George C Prendergast; Rakesh Kumar
Journal:  Cancer Res       Date:  2011-10-17       Impact factor: 12.701

4.  Clinical trials of endothelin antagonists in heart failure: publication is good for the public health.

Authors:  N F Kelland; D J Webb
Journal:  Heart       Date:  2007-01       Impact factor: 5.994

5.  Endothelin-1 shifts the mediator of bradykinin-induced relaxation from NO to H2 O2 in resistance arteries from patients with cardiovascular disease.

Authors:  Thomas M Leurgans; Maria Bloksgaard; Jonathan R Brewer; Luis A Bagatolli; Maise H Fredgart; Kristoffer Rosenstand; Maria L Hansen; Lars M Rasmussen; Akhmadjon Irmukhamedov; Jo Gr De Mey
Journal:  Br J Pharmacol       Date:  2016-04-06       Impact factor: 8.739

Review 6.  Pulmonary hypertension associated with sickle cell disease: pathophysiology and rationale for treatment.

Authors:  Raymond L Benza
Journal:  Lung       Date:  2008-05-10       Impact factor: 2.584

Review 7.  Endothelin receptors: what's new and what do we need to know?

Authors:  Stephanie W Watts
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2009-11-11       Impact factor: 3.619

Review 8.  Differential gene expression in glaucoma.

Authors:  Tatjana C Jakobs
Journal:  Cold Spring Harb Perspect Med       Date:  2014-07-01       Impact factor: 6.915

9.  Endothelin ET(B) receptors in arteries and veins: multiple actions in the vein.

Authors:  Nathan R Tykocki; Cheryl E Gariepy; Stephanie W Watts
Journal:  J Pharmacol Exp Ther       Date:  2009-03-18       Impact factor: 4.030

10.  Activation of native TRPC1/C5/C6 channels by endothelin-1 is mediated by both PIP3 and PIP2 in rabbit coronary artery myocytes.

Authors:  Sohag N Saleh; Anthony P Albert; William A Large
Journal:  J Physiol       Date:  2009-09-21       Impact factor: 5.182

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.